Bradley Corr, MD, believes these clinical trials focused on endometrial cancer are going to be influential in new treatments and therapies. A new drug class will be tested and is the first of its kind to be used in endometrial cancer.
The Phase II clinical trial aims to determine the effectiveness of the anti-cancer drug Rucaparib as maintenance therapy for patients with metastatic or recurrent endometrial cancer that have been treated initially with chemotherapy.
The Phase II clinical trial aims to determine the effectiveness of the anti-cancer drug Rucaparib as maintenance therapy for patients with metastatic or recurrent endometrial cancer that have been treated initially with chemotherapy.